awmsg logo



lenalidomide (Revlimid®)


Reference No. 2614

Publication date:
27/07/2016


Appraisal information

lenalidomide (Revlimid®) 2.5 mg capsule
lenalidomide (Revlimid®) 5 mg capsule
lenalidomide (Revlimid®) 7.5 mg capsule
lenalidomide (Revlimid®) 10 mg capsule
lenalidomide (Revlimid®) 15 mg capsule
lenalidomide (Revlimid®) 25 mg capsule
lenalidomide (Revlimid®) 20 mg capsule


Company: Celgene Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 08/06/2016
AWMSG meeting date: 13/07/2016
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 2116
Ministerial ratification: 26/07/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Lenalidomide (Revlimid®) is recommended as an option for restricted use within NHS Wales. Lenalidomide (Revlimid®) in combination with low-dose dexamethasone should be restricted for use within its licensed indication for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant and are unsuitable for thalidomide-containing regimens. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. Lenalidomide (Revlimid®) is not recommended for use within NHS Wales outside of this subpopulation.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download